Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

ALKERMES, INC.

Filed by SPLITOAK STRATEGIES LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
c46bb6b6-7752-4294-9bad-ff74797d94f4
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings; H.R. 4030, Treatment Continuity Act of 2025

Literal federal measure citations: H.R. 4030

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.